Status:
UNKNOWN
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
Lead Sponsor:
Zagazig University
Conditions:
Gestational Trophoblastic Disease
Eligibility:
FEMALE
20-40 years
Phase:
PHASE2
PHASE3
Brief Summary
Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)
Detailed Description
Management of hydatidiform mole is usually evacuation followed by β-hcg surveillance to early detect cases of GTN . The risk of developing GTN is reported to be 16% to 20% in women with CHM . GTN is a...
Eligibility Criteria
Inclusion
- Women were diagnosed to have CHM by ultrasound and confirmed by histopathological examination
Exclusion
- Metastatic disease associated with HM at presentation, in which situation chemotherapy, rather than prophylactic treatment, as prescribed,
- Late diagnosis of CHM made only by histological examination of curetted material
- Uterine evacuation at another hospital and patient seen at the optimum patient care only for follow up
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05203562
Start Date
June 1 2020
End Date
June 1 2023
Last Update
July 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamed ALI Alabiad
Zagazig, Sharqia Province, Egypt, 14150